FIELD : medicine; pharmaceuticals.SUBSTANCE : invention relates to a pharmaceutical composition which, while allowing or enables an effective and specific immune response to Aβ40 (produced antibodies are specific to Aβ40 without significant binding to Aβ42), increases the above response compared to response caused by other conjugates also containing CysAβ(33–40) peptide and KLH (keyhole limpet haemocyanin), where said elements are conjugated or conjugated by another cross-linking agent, which also enables peptide binding to transport protein.EFFECT : amyloid conjugate, applications and methods are disclosed.19 cl, 7 tbl, 5 ex